Back to search

Article

COVID-19 Vaccine-Induced Antibody and T Cell Responses in Immunosuppressed Patients with Inflammatory Bowel Disease After the Third Vaccine Dose

2022-07-25

Abstract excerpt

Background: COVID-19 vaccine-induced antibody responses are reduced in patients with inflammatory bowel disease (IBD) taking infliximab or tofacitinib after two vaccine doses. We sought to determine whether immunosuppressive treatments were associated with reduced antibody and T cell responses after a third vaccine dose. <br><br>Methods: 352 adults (72 healthy controls and 280 IBD) from the prospectively recruited...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
f5e3d8ea-3afa-522d-a49e-78a2822161a4
DOI
10.2139/ssrn.4172071
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
COVID-19 Vaccine-Induced Antibody and T Cell Responses in Immunosuppressed Patients with Inflammatory Bowel Disease After the Third Vaccine DoseDOI 10.2139/ssrn.4172071
COVID-19 Vaccine-Induced Antibody Responses are Impaired in IBD Patients Treated with Infliximab or Tofacitinib, but not Thiopurines, Ustekinumab or VedolizumabSemantic proximity
Serological response to COVID-19 vaccination in IBD patients receiving biologicsSemantic proximity
Favourable vaccine-induced SARS-CoV-2 specific T cell response profile in patients undergoing immune-modifying therapiesSemantic proximity
Third and fourth vaccine doses broaden and prolong immunity to SARS-CoV-2 in immunocompromised adult patientsSemantic proximity
Patients with Inflammatory Bowel Disease on anti-Tumor Necrosis Factor Therapy Might be Predisposed to SARS-CoV-2 Variants Infection Even after Receiving a Third mRNA Vaccine DoseSemantic proximity
Antibody Responses to SARS-CoV-2 after Infection or Vaccination in Children and Young Adults with Inflammatory Bowel DiseaseSemantic proximity
Neutralising Antibody Potency Against SARS-CoV-2 Ancestral and Omicron BA.1 and BA.4/5 Variants in Patients with Inflammatory Bowel Disease after Three Doses of COVID-19 Vaccine: A Prospective Multicentre Cohort Study (CLARITY)Semantic proximity
COVID-19 Vaccine Booster Dose Willingness Among Patients with Inflammatory Bowel Disease on Infliximab and Vedolizumab: A Cross-Sectional StudySemantic proximity
Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune mediated inflammatory diseasesSemantic proximity
Examining the Immunological Effects of COVID-19 Vaccination in Patients with Conditions Potentially Leading to Diminished Immune Response Capacity – The OCTAVE TrialSemantic proximity
Immune responses and disease biomarker long-term changes following COVID-19 mRNA vaccination in a cohort of rheumatic disease patientsSemantic proximity
Seroprevalence of Anti-Sars-CoV-2 Antibodies in Patients with Inflammatory Bowel DiseaseSemantic proximity
Select a neighboring publication to make it the new centre.